论文部分内容阅读
目的探讨纳洛酮在Ⅱ型呼吸衰竭肺性脑病治疗中的临床疗效并分析其安全性。方法将61例Ⅱ型呼吸衰竭肺性脑病患者随机分成对照组和治疗组。所有患者都给予积极控制感染措施,使患者能够持续低流量吸氧,给患者止咳化痰、解痉平喘以保证气道通畅,同时保持患者水、电解质及酸碱平衡。治疗组在此基础上注射纳洛酮液。比较两组的疗效及安全性。结果治疗结束时,治疗组的总有效率显著高于对照组(P<0.05),动脉血二氧化碳分压(PaCO2)显著低于对照组(P<0.05),动脉血氧分压(PaO2)显著高于对照组(P<0.05),治疗过程中未出现明显不良反应。结论利用纳洛酮对Ⅱ型呼吸衰竭肺性脑病进行治疗,疗效良好,能够明显改善患者的动脉血气状况,安全可靠,值得临床推广使用。
Objective To investigate the clinical efficacy of naloxone in the treatment of pulmonary encephalopathy in type Ⅱ respiratory failure and analyze its safety. Methods Sixty-one patients with respiratory failure type II pulmonary encephalopathy were randomly divided into control group and treatment group. All patients were given positive control of infection measures, so that patients can continue low flow oxygen, cough and phlegm to patients, spasm asthma to ensure airway patency, while maintaining the patient’s water, electrolyte and acid-base balance. The treatment group was injected with naloxone solution on this basis. The curative effect and safety of the two groups were compared. Results At the end of treatment, the total effective rate of the treatment group was significantly higher than that of the control group (P <0.05). The PaCO2 of arterial blood was significantly lower than that of the control group (P <0.05) Higher than the control group (P <0.05), no obvious adverse reactions during the treatment. Conclusions The use of naloxone in the treatment of pulmonary encephalopathy of respiratory failure type Ⅱ, with good effect, can significantly improve the patient’s arterial blood gas situation, safe and reliable, worthy of clinical promotion and use.